Related by context. All words. (Click for frequent words.) 70 androgen independent 69 K ras mutations 69 Gleevec resistant 69 luteinizing hormone releasing 68 leukemia AML 68 castration resistant prostate cancer 68 carcinoma HCC 68 androgen receptor AR 67 prostate carcinoma 67 castrate resistant 67 metastatic colorectal 67 syngeneic 67 hormone refractory 67 epithelial tumors 67 neurofibromas 67 GISTs 67 pancreatic adenocarcinoma 66 TTR gene 66 colon carcinoma 66 GRNOPC1 contains 66 HER2 receptor 66 metastatic gastric 66 LHRH receptor positive 66 pharmacokinetic interactions 66 Leukemias 66 imatinib Gleevec ® 66 myelofibrosis polycythemia vera 66 adriamycin 66 hepatoma 66 colorectal carcinoma 66 castrate resistant prostate cancer 65 leukemia CLL 65 pancreatic prostate 65 KRAS oncogene 65 Carcinoid tumors 65 anaplastic 65 Fludarabine 65 vinca alkaloids 65 GSTP1 65 T#I [002] 64 tumors GIST 64 resistant hormone refractory 64 TNF blocker therapy 64 KRAS mutant 64 systemic anaplastic large 64 imatinib Gleevec 64 ADPKD 64 Vidaza ® 64 ovarian carcinoma 64 CYT# potent vascular disrupting 64 sarcomatoid 64 MALT lymphoma 64 cell lymphoma ALCL 64 bleomycin 64 cisplatin resistant 64 progesterone receptor negative 64 EGFR mutant 64 nonmetastatic 64 urothelial carcinoma 64 metastatic malignant 64 peritoneal carcinomatosis 64 5alpha reductase 64 atypical hyperplasia 64 chemoresistant 64 dasatinib Sprycel 64 cervical carcinoma 64 myeloproliferative disorders 64 tumor xenograft models 64 BRCA deficient 64 carcinoid tumors 64 gastrointestinal stromal tumor 64 CDK inhibitor 64 interferon IFN 64 FLT3 64 situ CIS 64 ERBB2 64 demonstrated antitumor activity 64 WT1 64 pancreatic carcinoma 63 pulmonary metastases 63 Leydig cell 63 cyclin dependent kinase inhibitor 63 Endometrial 63 castration resistant hormone refractory 63 cathepsins 63 antiproliferative effects 63 HER2 positive breast 63 T#I mutant 63 metaplasia 63 hormone LHRH 63 ErbB2 positive 63 dasatinib Sprycel ® 63 EGFR protein 63 metastatic castration resistant 63 alpha folate receptor 63 V#F mutation 63 relapsed ovarian cancer 63 mucinous 63 CCL# 63 relapsed leukemia 63 endocrine therapies 63 Squamous 63 HER2 neu 63 Papillary 63 erlotinib Tarceva ® 63 neoplasias 63 neovasculature 63 myelodysplastic myeloproliferative diseases 63 HER2 overexpression 63 protein tyrosine phosphatase 1B 63 myeloproliferative diseases 63 resectable 63 IDH mutations 63 myeloproliferative neoplasms 63 gefitinib Iressa 63 nonsmall cell lung cancer 63 PDGFR 63 pancreatic endocrine 63 tumorigenicity 63 Ceflatonin 63 epithelioid 63 pancreatic lung 63 fallopian tube carcinoma 63 gastric carcinoma 63 cyclin E 63 cell lymphoma CTCL 63 monocytic 63 adrenocortical cancer 63 Carcinomas 63 atypical hemolytic uremic syndrome 63 allogeneic HSCT 63 Aurora kinase 63 proto oncogene 63 unresectable tumors 63 papillary carcinoma 63 AGTR1 63 squamous cell carcinoma SCC 63 benign neoplasms 63 pancreatic neuroendocrine tumors 63 pancreatic colon 63 neuroendocrine carcinoma 62 recurrent NSCLC 62 interferon alfa 62 HepG2 cells 62 nucleoside analog 62 Hurthle cell 62 Multiple Myeloma MM 62 CDK4 62 histone deacetylases 62 Cutaneous T 62 prostate cancer HRPC 62 hormone receptor negative 62 lymph node metastasis 62 gastric adenocarcinoma 62 molecule epidermal 62 essential thrombocythemia ET 62 chemo resistant 62 medically inoperable 62 lung carcinomas 62 HER2 HER2 62 cytotoxin 62 hepatocellular carcinomas 62 gastrointestinal stromal tumors 62 CTAP# Capsules 62 transgene expression 62 imatinib resistant 62 orally administered inhibitor 62 Epidermal Growth Factor Receptor 62 accumulate preferentially 62 MAGE A3 ASCI 62 urothelial bladder cancer 62 Hashimoto thyroiditis 62 CD#c 62 Glioblastoma Multiforme 62 metastatic carcinoma 62 non resectable metastatic 62 pheochromocytoma 62 ErbB2 62 lymphocyte activation 62 Clusterin 62 Bleomycin 62 IGF1R 62 ovarian breast 62 recurrent glioblastoma 62 ADAM# 62 Sezary syndrome 62 Factor Receptor 62 Diffuse Large B 62 alkylating agent 62 HER1 62 ERK1 2 62 hypermethylated 62 trastuzumab Herceptin ® 62 EGFr 62 APOPTONE 62 depsipeptide 62 Voreloxin 62 BRAF V#E mutation 62 mRCC 62 Advanced Renal Cell 62 antiangiogenic therapy 62 glutamyl 62 stage IIIB 62 5 HT4 62 Dasatinib 62 endometrial hyperplasia 62 pituitary adenomas 62 renal cell carcinomas 62 endostatin 62 pleomorphic 62 Neuvenge 62 metastatic bladder 62 taxane resistant 62 mediated inhibition 62 TRAIL induced apoptosis 62 Xanafide 62 pDC 62 LHRH 62 EGFR tyrosine kinase inhibitor 62 skeletal metastases 62 prostate cancer CRPC 62 efaproxiral 62 mutated KRAS 62 c MYC 62 lung fibrosis 62 poorer prognosis 62 papillary renal cell carcinoma 62 Raf MEK ERK 62 lymphocytic leukemia 62 MAPK pathway 62 basal cell carcinoma BCC 62 methylenetetrahydrofolate reductase 62 prostate pancreatic 62 small lymphocytic lymphoma 62 Adjuvant chemotherapy 62 cyclin dependent kinase 62 Ribavirin causes 62 medullary thyroid cancer 62 metastatic hormone refractory 61 somatostatin 61 Taxol ® 61 LRP5 61 prostate cancer AIPC 61 Fibroblasts 61 malignant ascites 61 Sudhir Agrawal D.Phil 61 GW# [003] 61 soluble tumor necrosis 61 Carcinoma 61 pancreatic islet cell 61 C EBP alpha 61 radiosensitivity 61 5 fluorouracil leucovorin 61 miRNA genes 61 LRAT 61 Nilotinib 61 LHRH analogues 61 Bezielle 61 xenografts 61 acute myelogenous leukemia AML 61 thymoma 61 GNAQ 61 NKG2D 61 taxane refractory 61 alkylating agents 61 HNSCC 61 missense mutation 61 Letairis ambrisentan 61 bexarotene 61 parathyroid carcinoma 61 hamartomas 61 Philadelphia Chromosome Positive 61 granzyme B 61 invasive ductal 61 Basal cell 61 epithelial ovarian 61 breast carcinomas 61 leukemia ALL 61 subependymal giant cell 61 cells overexpressing 61 NF kB pathway 61 renal carcinoma 61 alpha2 61 ovarian lung 61 ductal breast cancer 61 SOD2 gene 61 colorectal adenocarcinoma 61 gastrointestinal stromal tumors GIST 61 nodal metastasis 61 neoplastic 61 Janus kinase 61 EGFR mutation positive 61 gemcitabine carboplatin 61 neoplasia 61 KIT mutations 61 miR #a [001] 61 CYP#A# CYP#D# 61 breast pancreatic 61 pheochromocytomas 61 pancreatic NET 61 breast carcinoma 61 taxane chemotherapy 61 mutational status 61 Paraplatin ® 61 EGFR mutation 61 cholangiocarcinoma 61 sorafenib Nexavar 61 c MET 61 JAK2 enzyme 61 xenograft models 61 LymphoStat B belimumab 61 FUSILEV enhances 61 carcinomas 61 essential thrombocythemia 61 Safinamide 61 chemokine receptor 61 papillary RCC 61 differentiated thyroid 61 neuroendocrine cancers 61 PC3 cells 61 sunitinib Sutent ® 61 regulated kinase 61 invasive lobular 61 xenograft tumors 61 Mesenchymal 61 Chronic lymphocytic leukemia CLL 61 haematopoietic 61 astrocytomas 61 chronic eosinophilic leukemia 61 oligodendroglioma 61 hA# 61 situ LCIS 61 Flt3 61 interleukin IL -# 61 HCV protease 61 MYCN amplification 61 corticosteroid dexamethasone 61 HBeAg negative 61 carcinoma mCRC 61 gastric cancers 61 hepatocellular cancer 61 PSMA ADC 61 PCa 61 novel VDA molecule 61 nucleoside analogue 61 FOLFOX6 61 papillary 61 inducible nitric oxide synthase 61 Metastatic 61 histological subtype 61 Hormone Refractory Prostate Cancer 61 activin 61 SSc 61 gemcitabine chemotherapy 61 germline mutations 61 recurrent ovarian 61 NSCLC tumors 61 breast endometrial 61 biliary tract cancer 61 ara C 61 estramustine 61 cell adhesion molecule 61 HER-2/neu 61 seminoma 61 p# deficient 61 Lenalidomide 61 EGF receptor 61 gastrointestinal stromal tumors GISTs 61 radiation chemoradiation 61 Uricase PEG 61 cirrhosis liver failure 61 leukemias lymphomas 61 irinotecan doxorubicin oxaliplatin paclitaxel 61 Myelodysplastic Syndrome MDS 61 steroidogenesis 61 invasive lobular carcinoma 61 acute myeloid 61 PNET 61 Her2/neu 61 NFkB 61 gastrointestinal stromal tumor GIST 60 transplantation HCT 60 malignant ovarian 60 seminal vesicle 60 LNCaP cells 60 grade cervical intraepithelial 60 p# mitogen activated 60 ERK pathway 60 selective modulator 60 prostate epithelial cells 60 ALK inhibitor 60 mycosis fungoides 60 node metastases 60 liver scarring 60 mesotheliomas 60 operable breast cancer 60 IGFBP2 60 metastatic pancreatic 60 HER2/neu 60 cMET 60 invasive carcinoma 60 cervical lymph nodes 60 DHFR 60 D aspartate NMDA receptor 60 cisplatin gemcitabine 60 histologies 60 relapsed MM 60 squamous cell lung cancer 60 familial amyloidotic polyneuropathy FAP 60 Azacitidine 60 Metastatic breast cancer 60 VEGFR1 60 pan HDAC inhibitor 60 pemphigus vulgaris 60 Chronic pancreatitis 60 cetuximab Erbitux R 60 RRM1 60 paragangliomas 60 Alessandro Riva 60 KRAS mutations 60 MTHFR 60 bladder carcinoma 60 FGFR3 60 selectively inhibited 60 PAOD 60 prostate cancer CaP 60 Akt activation 60 BCG refractory carcinoma 60 INCB# [003] 60 BRAF V#E 60 C#Y 60 cytotoxic effects 60 CDK cyclin dependent 60 precancerous condition 60 paclitaxel Taxol 60 asymptomatic metastatic 60 chronic myeloid 60 metastatic kidney 60 alkaline phosphatase ALP 60 lobular carcinoma 60 Refractory Hodgkin Lymphoma 60 E#F# 60 chemokine receptors 60 non mutated KRAS 60 alkylating 60 colorectal pancreatic 60 glutamic acid decarboxylase 60 isoenzyme 60 malignant pleural mesothelioma 60 c myc 60 myelomas 60 FGFR1 60 Squamous cell 60 nilotinib Tasigna ® 60 transgenic mouse model 60 stage IIIb IV 60 refractory chronic lymphocytic 60 NS4A 60 Pemetrexed 60 colorectal gastric 60 chemotherapy cisplatin 60 mutated p# 60 cyclooxygenase 60 trabectedin 60 gastric carcinomas 60 secondary hyperparathyroidism 60 fulvestrant 60 tyrosine kinase inhibitors TKIs 60 4E BP1 60 Cryptococcus neoformans 60 TRAIL R2 60 null mice 60 anti angiogenic therapy 60 leiomyomas 60 liposomal amphotericin B 60 small molecule tyrosine 60 anthracyclines taxanes 60 orthotopic model 60 Heterozygous 60 cancer mCRC 60 hypereosinophilic syndrome 60 epithelial cancers 60 fallopian tube cancers 60 unresectable stage 60 recurrent glioblastoma multiforme 60 HGPIN 60 mineralocorticoid receptor 60 E cadherin expression 60 PI3K Akt 60 androgen deprivation 60 PDE#A 60 metaglidasen 60 curative resection 60 PC# cells 60 neoplastic cells 60 GPNMB 60 HER2 negative 60 evaluating picoplatin 60 GSTT1 60 Histologically 60 PEGylated Fab fragment 60 BRAF mutations 60 TNF α 60 EGFR tyrosine kinase inhibitors 60 mTOR inhibitors 60 vinca alkaloid 60 cytoreduction 60 malignant pancreatic 60 TGF alpha 60 Vandetanib 60 HER2 positive 60 CDH1 60 Antitumor Activity 60 adenocarcinomas 60 chronic myelogenous leukemia CML 60 Hepatocellular Carcinoma HCC 60 refractory colorectal cancer 60 overexpress 60 prostate ovarian 60 hyperplasia BPH 60 potent inducer 60 mTOR inhibitor 60 MGUS 60 bevacizumab Avastin R 60 hepatocellular carcinoma HCC 60 HMG CoA reductase inhibitors 60 Kinoid 60 kidney urologic 60 Systemic lupus erythematosus 60 MKC# MT 60 pegylated liposomal doxorubicin 60 lymphoid organs 60 erlotinib Tarceva 60 imatinib resistance 60 epithelial cells lining 60 Cisplatin 60 CD8 + cytotoxic 60 monocyte chemoattractant protein 60 HLA DR4 60 MAGE A3 60 Epothilone D 60 indolent follicular non 60 PHD2 60 hormone deprivation 60 specific lectin receptors 60 eIF 4E 60 advanced metastatic prostate 60 treat benign prostatic 60 extracellular domain 60 oncoproteins 60 trans retinoic acid 60 bladder ovarian 60 Soft Tissue Sarcoma 60 gemcitabine Gemzar ® 60 radiation sensitizer 60 testicular germ cell 60 somatostatin receptors 60 deCODE ProstateCancer TM 60 Bosutinib 60 dexpramipexole 60 hyperplastic 60 induce apoptosis 60 lung adenocarcinoma 60 estrogen receptor ER 60 contralateral breast 60 Peginterferon alfa 2b 60 COX2 60 polycythemia vera essential thrombocythemia 60 ovarian pancreatic 60 pT2 60 EGFR TKI 60 mycophenolate mofetil 60 refractory indolent non 60 DFMO 60 IGF IR 60 selective inhibition 60 Ph + acute lymphoblastic 60 histologic subtype 60 anti androgen 60 malignant lymphoma 60 HER2 positive metastatic breast 60 p# MAPK 60 cutaneous T 60 immunodeficiency disorders 60 alpha1 antitrypsin AAT deficiency 60 lymphomas leukemias 60 Follicular Lymphoma 60 activated lymphocytes 60 CYP#B# 60 Epratuzumab 59 malignant prostate 59 poly ADP ribose polymerase 59 precursor lesions 59 intravesical therapy 59 Î ² 59 Irinotecan 59 ErbB 59 daunorubicin 59 RhuDex R 59 HER2 expression 59 bladder cancers 59 EGFR HER2 59 Antitumor activity 59 HGS ETR1 mapatumumab 59 prostate carcinomas 59 metastatic androgen independent 59 standard chemotherapy regimens 59 refractory cutaneous T 59 Monocyte 59 uterine tumors 59 demethylating agent 59 T1a 59 metastatic renal cell 59 complement inhibitor eculizumab 59 Aromatase 59 Atypical Hemolytic Uremic Syndrome 59 cyclin dependent kinases CDKs 59 receptor tyrosine kinase 59 lymphoid malignancies 59 HIF 1α 59 orthotopic 59 Degarelix 59 adhesion molecule EpCAM expressing 59 Kit CD# positive 59 FGFR2 59 Glufosfamide 59 homodimers 59 carcinoembryonic antigen 59 surface glycoprotein 59 pediatric acute lymphoblastic 59 LHRH agonists 59 CCR5 delta# 59 surgical debulking 59 acute humoral rejection 59 protein tyrosine phosphatase 59 relapsed Acute Myeloid 59 LRP6 59 caveolin 1 59 ABCB1 59 Malignant Melanoma 59 metastatic adenocarcinoma 59 trastuzumab Herceptin R 59 Aplidin 59 myelofibrosis MF 59 mutant KRAS 59 CD# expressing 59 EGFRvIII 59 EGFR inhibitors 59 Acute myeloid leukemia AML 59 AMN# [001] 59 polyglutamate 59 Vidaza azacitidine 59 flavopiridol 59 squamous histology 59 intraperitoneal injection 59 PTHrP 59 metastatic lung cancer 59 metachronous 59 cetuximab Erbitux ® 59 kinase inhibition 59 TET2 59 IMA# 59 liver metastasis 59 intraepithelial neoplasia 59 myeloproliferative 59 Erlotinib 59 N cadherin 59 esophagogastric junction 59 evaluating tivozanib 59 opioid induced constipation OIC 59 Activating mutations 59 premalignant 59 receptor inhibitor 59 Relapsed Refractory 59 NMIBC 59 chimeric monoclonal antibody 59 virotherapy 59 Imatinib mesylate 59 Naive Patients 59 lymphocytic 59 receptor tyrosine kinase inhibitor 59 adecatumumab 59 immunomodulatory properties 59 hepatic lipase 59 Personalized Immunotherapy 59 chronic granulomatous disease 59 BRAF mutation 59 cellular prion protein 59 cytopenias 59 Cremophor 59 antibody MT# 59 metastatic renal 59 Myelofibrosis 59 2 methoxyestradiol 59 thymidylate synthase 59 lymphoid tissue 59 thyrotropin 59 imatinib therapy 59 Zolinza 59 Abl 59 GIST tumors 59 3 carbinol 59 intravenous belinostat 59 demethylating agents 59 Pfizer Camptosar 59 chemopreventive agent 59 HER2 amplified 59 Surgical resection 59 apoptosis induced 59 VEGFR2 inhibitor 59 neurotrophic 59 oligodendrocyte progenitor cells 59 grade gliomas 59 caveolin 59 androgen dependent 59 downregulated 59 PCNSL 59 Immunohistochemical analysis 59 paraganglioma 59 miR #b [001] 59 Chemoradiation 59 docetaxel Taxotere ® 59 Imatinib 59 hypercalcemia 59 Anaplastic 59 TNFa 59 sulfasalazine 59 metastatic RCC 59 Non Alcoholic Steatohepatitis 59 RANTES 59 S/GSK# 59 chromosomal rearrangement 59 alvespimycin 59 lichen planus 59 lipoxygenase 59 Cyclooxygenase 2 59 Anthracycline 59 TTF Therapy 59 endometrial cancers 59 myeloid 59 SHANK3 59 Tumor Necrosis Factor 59 Doxorubicin 59 untreated metastatic melanoma 59 Basal Cell 59 carcinoid 59 anti EGFR antibody 59 endometrial carcinoma 59 metastatic castrate resistant 59 targeted radiotherapeutic 59 irreversible inhibitor 59 MUC1 59 prostate adenocarcinoma 59 melatonin receptor 59 metastatic colorectal carcinoma 59 prognostic indicator 59 SERMs 59 colorectal lung 59 oligodendrogliomas 59 metastatic ovarian cancer 59 Pralatrexate 59 constitutively expressed 59 hematopoietic cancers 59 chemotherapeutic agent 59 BRCA1 BRCA2 59 p#HER# positive 59 Omacetaxine 59 mutated K ras 59 idarubicin 59 receptor alpha 59 Vorinostat 59 Enzastaurin 59 HLA DR 59 busulfan 59 commonly mutated genes 59 Cell Lymphoma CTCL 59 solar keratosis 59 ERK signaling 59 interferon γ 59 Annamycin 59 pDCs 59 Panzem R 59 tryptase 59 Capecitabine 59 neurofibroma 59 MCF7 cells 59 acute GvHD 59 Interferon alpha 59 Neoadjuvant 59 paclitaxel cisplatin 59 hormone refractory prostate 59 endometrioid 59 thymidylate synthase TS 59 thioredoxin 59 mTOR mammalian target 59 bevacizumab Avastin ® 59 BRAF mutant 59 XL# inhibits 59 locoregional 59 lymphoma subtypes 59 herpes zoster shingles 59 Epstein Barr Virus EBV 59 malignant transformation 59 unresectable locally advanced 59 malignant lymphomas 59 pancreatic ovarian 59 CD#b 59 surgically resectable 59 decitabine 59 metastatic renal cell carcinoma 59 epithelia 59 neoadjuvant therapy 59 oxysterols 59 IFN gamma 59 precursor acute lymphoblastic 59 cell acute lymphoblastic 59 TrkA 59 basal cells 59 Immunohistochemical staining 59 IFN beta 59 Everolimus 59 inherited mutations 59 XYOTAX TM 59 cell carcinomas 59 hormone refractory prostate cancer 59 cediranib 59 serine protease 59 myelodysplastic syndromes MDS 59 CYC# 59 glucocorticoid receptors 59 N Myc 59 vaginal candidiasis 59 trastuzumab Herceptin 59 estrogen receptor negative 59 gemcitabine Gemzar 59 SNP rs# [002] 59 BMPR2 59 paclitaxel Taxol ® 59 mouse xenograft models 59 gemcitabine cisplatin 59 TGF β 59 Metastases 58 annexin 58 Orally administered 58 Aflibercept 58 apocrine 58 lactate dehydrogenase 58 stage IIIA 58 proteasome inhibitor 58 irinotecan containing 58 Adjuvant Treatment 58 Phase #/#a trial 58 Fibroblast 58 Cathepsin B 58 Epstein Barr virus EBV 58 erythematosus 58 upregulates 58 B7 H3 58 Interferon beta 58 patients receiving myelosuppressive 58 nasopharyngeal carcinoma 58 androgen ablation therapy 58 paclitaxel poliglumex 58 conventional DMARDs 58 ductal carcinomas 58 metastatic malignant melanoma 58 Src kinase 58 trophoblasts 58 glycosylated 58 advanced pancreatic neuroendocrine 58 PTPN# 58 benign moles 58 MSH2 58 Leydig cells 58 interleukin IL 58 refractory metastatic 58 Nucleoside 58 TACI Ig 58 adjuvant radiotherapy 58 chronic lymphocytic 58 relapsed SCLC 58 Genasense ® 58 B CLL 58 premalignant lesions 58 COL#A# 58 cytokeratin 58 zanolimumab 58 TRAIL R1 58 seminomas 58 neuroblastoma tumors 58 post transplant lymphoproliferative 58 meropenem 58 refractory chronic myeloid 58 dyskeratosis congenita 58 lactate dehydrogenase LDH 58 fibrosarcoma 58 haematologic 58 SPINK1 58 advanced epithelial ovarian 58 mutated BRAF gene 58 sphingosine 1 58 5HT 58 constitutively active 58 carmustine 58 Lyn kinase 58 inhibitory receptor 58 histologically 58 hormone LHRH antagonist 58 MLL AF9 58 beta estradiol 58 TCF#L# gene 58 EphB4 58 ChR2 58 HGS ETR2 58 dermatofibrosarcoma protuberans 58 pAkt 58 TNFalpha 58 metastatic liver 58 sorafenib tablets 58 Li Fraumeni 58 III EGFRvIII 58 experimental autoimmune encephalomyelitis 58 6 mercaptopurine 58 Lymphocytic 58 lymphocytosis 58 stage IIIB IV 58 ALK inhibitors 58 Cytarabine 58 spontaneously regress 58 metastatic neuroendocrine tumors 58 Waldenstrom macroglobulinemia 58 JAK inhibitors 58 sorafenib Nexavar ® 58 Gorlin syndrome 58 liposomal formulation 58 pro angiogenic 58 IV NSCLC 58 VIPR2 58 lenalidomide Revlimid R 58 BMS# 58 Pim kinases 58 Albuferon TM 58 refractory NSCLC 58 seliciclib 58 pathophysiological effects 58 B Raf 58 PTLD 58 KRAS wild 58 R Saizen R 58 endothelin receptor 58 endoplasmic reticulum stress 58 Acute Myeloid Leukaemia AML 58 erythematosus SLE 58 LKB1 58 p# mutation 58 herpesviruses 58 cytolytic 58 virally induced 58 carbohydrate polymer 58 oral clodronate 58 lymphangiogenesis 58 hCG Beta 58 thalidomide Thalomid 58 RAV# 58 solar keratoses 58 ErbB1 58 mitochondrial toxicity 58 LNCaP 58 HCV replicon 58 p# activation 58 Acute Myelogenous Leukemia AML 58 follicular lymphomas 58 precancerous tissues 58 acute leukemias 58 Paraplatin ® carboplatin 58 MLH1 58 anaplastic lymphoma kinase ALK 58 refractory Hodgkin 58 whose tumors overexpress 58 dysplastic lesions caused 58 CYP#A# [002] 58 antiandrogen 58 missense mutations 58 autoantibody positive 58 Bcr Abl T#I mutation 58 adenomatous 58 PKM2 58 compound AEZS 58 basal cell nevus syndrome 58 chemotherapeutic drug 58 normal karyotype 58 docetaxel chemotherapy 58 IL 1beta 58 BCR ABL protein 58 heavily pretreated 58 anthracycline containing 58 localized renal 58 dacarbazine DTIC 58 hormone receptor positive